BRPI0807828B8 - composição compreendendo leveduras e usos das mesmas, bem como método para o crescimento de leveduras e kit para o cultivo de leveduras - Google Patents

composição compreendendo leveduras e usos das mesmas, bem como método para o crescimento de leveduras e kit para o cultivo de leveduras

Info

Publication number
BRPI0807828B8
BRPI0807828B8 BRPI0807828A BRPI0807828A BRPI0807828B8 BR PI0807828 B8 BRPI0807828 B8 BR PI0807828B8 BR PI0807828 A BRPI0807828 A BR PI0807828A BR PI0807828 A BRPI0807828 A BR PI0807828A BR PI0807828 B8 BRPI0807828 B8 BR PI0807828B8
Authority
BR
Brazil
Prior art keywords
yeasts
growing
kit
composition
well
Prior art date
Application number
BRPI0807828A
Other languages
English (en)
Inventor
Franzusoff Alex
Quick Deborah
Original Assignee
Globeimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Globeimmune Inc filed Critical Globeimmune Inc
Publication of BRPI0807828A2 publication Critical patent/BRPI0807828A2/pt
Publication of BRPI0807828B1 publication Critical patent/BRPI0807828B1/pt
Publication of BRPI0807828B8 publication Critical patent/BRPI0807828B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

composição compreendendo leveduras e usos das mesmas, bem como método para o crescimento de leveduras e kit para o cultivo de leveduras . a invenção fornece métodos para o cultivo de leveduras em um nível de ph neutro. as leveduras cultivadas sob condições de ph neutro exibem características desejáveis úteis para fins biológicos como, por exemplo, o desenvolvimento de vacinas, substâncias profiláticas e terapêuticas. a invenção também fornece composições e kits que compreendem leveduras desenvolvidas com o uso das metodologias aqui reveladas.
BRPI0807828A 2007-02-02 2008-02-01 composição compreendendo leveduras e usos das mesmas, bem como método para o crescimento de leveduras e kit para o cultivo de leveduras BRPI0807828B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89928107P 2007-02-02 2007-02-02
US60/899,281 2007-02-02
PCT/US2008/052843 WO2008097863A2 (en) 2007-02-02 2008-02-01 Methods for producing yeast-based vaccines

Publications (3)

Publication Number Publication Date
BRPI0807828A2 BRPI0807828A2 (pt) 2014-08-05
BRPI0807828B1 BRPI0807828B1 (pt) 2018-05-29
BRPI0807828B8 true BRPI0807828B8 (pt) 2021-05-25

Family

ID=39682350

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0807828A BRPI0807828B8 (pt) 2007-02-02 2008-02-01 composição compreendendo leveduras e usos das mesmas, bem como método para o crescimento de leveduras e kit para o cultivo de leveduras

Country Status (17)

Country Link
US (2) US9066893B2 (pt)
EP (1) EP2121013B1 (pt)
JP (2) JP5570819B2 (pt)
KR (2) KR20150006022A (pt)
CN (2) CN101687030B (pt)
AU (1) AU2008214029B2 (pt)
BR (1) BRPI0807828B8 (pt)
CA (1) CA2676783C (pt)
DK (1) DK2121013T3 (pt)
ES (1) ES2527756T3 (pt)
IL (2) IL200176A (pt)
MX (1) MX2009008175A (pt)
PL (1) PL2121013T3 (pt)
PT (1) PT2121013E (pt)
SG (2) SG10201405420QA (pt)
SI (1) SI2121013T1 (pt)
WO (1) WO2008097863A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102370974B (zh) 2002-12-16 2014-09-17 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
CN102614510A (zh) 2004-10-18 2012-08-01 全球免疫股份有限公司 基于酵母的对慢性丙型肝炎感染的治疗
KR20080043775A (ko) * 2005-07-11 2008-05-19 글로브이뮨 표적 치료용 회피 돌연변이체에 대한 면역 반응의 유발방법 및 조성물
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
BRPI0709340A2 (pt) 2006-03-27 2013-04-16 Globeimmune, Inc. mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma
AU2008214029B2 (en) * 2007-02-02 2014-01-30 Globelmmune, Inc. Methods for producing yeast-based vaccines
EP2134358A1 (en) * 2007-03-19 2009-12-23 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
JP2012503011A (ja) 2008-09-19 2012-02-02 グローブイミューン，インコーポレイテッド 慢性ｃ型肝炎ウイルス感染の免疫療法
KR101781966B1 (ko) 2009-04-17 2017-09-27 글로브이뮨 암에 대한 병용 면역요법 조성물 및 방법
AU2010291985B2 (en) 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
EA028659B1 (ru) 2011-02-12 2017-12-29 Глоубиммьюн, Инк. Терапевтическое средство на основе дрожжей для лечения хронического гепатита b
RU2690180C2 (ru) 2011-03-17 2019-05-31 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей с brachyury
BR112013032381B1 (pt) 2011-06-14 2021-01-12 Globeimmune, Inc. composições à base de levedura e métodos para o tratamento ou prevenção de infecção pelo vírus da hepatite delta
KR102049928B1 (ko) 2011-08-17 2019-11-28 글로브이뮨 효모-muc1 면역요법 조성물 및 그 용도
SG11201408652SA (en) 2012-06-26 2015-01-29 Biodesix Inc Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
MX374829B (es) 2013-03-19 2025-03-06 Globeimmune Inc Composición a base de levadura para usarse para tratar cordoma.
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
US10226522B2 (en) 2013-08-30 2019-03-12 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
US10799567B2 (en) 2014-04-11 2020-10-13 Globeimmune, Inc. Yeast-based immunotherapy and type I interferon sensitivity
WO2017023840A1 (en) 2015-08-03 2017-02-09 Globeimmune, Inc. Modified yeast-brachyury immunotherapeutic compositions
WO2019222073A1 (en) * 2018-05-15 2019-11-21 Globeimmune, Inc. Lysates of recombinant yeast for inducing cellular immune responses
US11311603B2 (en) 2018-06-19 2022-04-26 Nantcell, Inc. HIV treatment compositions and methods
US20210290708A1 (en) 2018-09-21 2021-09-23 Nantcell, Inc. Methods and compositions for modulating myeloid-derived suppressor cells

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) * 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) * 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5310654A (en) * 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5234830A (en) * 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
JP3510639B2 (ja) 1991-06-28 2004-03-29 カルピス株式会社 インターロイキン産生能を調節する機能を持たせた機能性食品又は健康食品
JP3091851B2 (ja) 1992-11-06 2000-09-25 工業技術院長 哺乳類の高マンノース型糖蛋白質糖鎖の酵母による製造法
US5830463A (en) * 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5413914A (en) * 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5858378A (en) * 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
WO1998035049A1 (en) * 1997-02-07 1998-08-13 Oriental Yeast Co., Ltd. Recombinant yeast pdi and process for preparing the same
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
EP1272213B1 (en) * 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
WO2002039951A2 (en) * 2000-11-15 2002-05-23 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
JP4288862B2 (ja) * 2001-03-30 2009-07-01 トヨタ自動車株式会社 プレニルアルコールの製造方法
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
CN102370974B (zh) * 2002-12-16 2014-09-17 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
KR100507665B1 (ko) 2003-03-25 2005-08-10 김경숙 페리틴 이형집합체를 효모 내에서 발현시키기 위한 벡터 및 상기 발현벡터로 형질전환 시킨 재조합 효모
CN102614510A (zh) * 2004-10-18 2012-08-01 全球免疫股份有限公司 基于酵母的对慢性丙型肝炎感染的治疗
JP4904086B2 (ja) * 2005-05-25 2012-03-28 公益財団法人微生物化学研究会 クラゲ類の分解廃液の処理装置及び処理方法、並びに微生物
KR20080043775A (ko) * 2005-07-11 2008-05-19 글로브이뮨 표적 치료용 회피 돌연변이체에 대한 면역 반응의 유발방법 및 조성물
US20070172503A1 (en) * 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
WO2007092792A2 (en) * 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
BRPI0709340A2 (pt) * 2006-03-27 2013-04-16 Globeimmune, Inc. mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma
AU2008214029B2 (en) 2007-02-02 2014-01-30 Globelmmune, Inc. Methods for producing yeast-based vaccines
EP2134358A1 (en) * 2007-03-19 2009-12-23 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
JP2012503011A (ja) 2008-09-19 2012-02-02 グローブイミューン，インコーポレイテッド 慢性ｃ型肝炎ウイルス感染の免疫療法
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
KR101781966B1 (ko) 2009-04-17 2017-09-27 글로브이뮨 암에 대한 병용 면역요법 조성물 및 방법
AU2010291985B2 (en) 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
US20130121964A1 (en) 2010-03-14 2013-05-16 Globeimmune, Inc. Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy

Also Published As

Publication number Publication date
US9549970B2 (en) 2017-01-24
PT2121013E (pt) 2015-02-04
WO2008097863A3 (en) 2008-11-20
SI2121013T1 (sl) 2015-02-27
WO2008097863A2 (en) 2008-08-14
SG171577A1 (en) 2011-06-29
CA2676783A1 (en) 2008-08-14
AU2008214029A1 (en) 2008-08-14
JP2014223072A (ja) 2014-12-04
EP2121013B1 (en) 2014-10-15
ES2527756T3 (es) 2015-01-29
CN104120086A (zh) 2014-10-29
KR20090116757A (ko) 2009-11-11
SG10201405420QA (en) 2014-10-30
IL237406A0 (en) 2015-04-30
HK1136979A1 (en) 2010-07-16
EP2121013A2 (en) 2009-11-25
JP5570819B2 (ja) 2014-08-13
CN101687030A (zh) 2010-03-31
PL2121013T3 (pl) 2015-05-29
BRPI0807828A2 (pt) 2014-08-05
CA2676783C (en) 2016-04-05
US20100189749A1 (en) 2010-07-29
IL200176A (en) 2015-10-29
KR20150006022A (ko) 2015-01-15
KR101555641B1 (ko) 2015-09-24
JP2010517537A (ja) 2010-05-27
IL200176A0 (en) 2010-04-15
MX2009008175A (es) 2009-08-12
US9066893B2 (en) 2015-06-30
US20130309269A1 (en) 2013-11-21
AU2008214029B2 (en) 2014-01-30
BRPI0807828B1 (pt) 2018-05-29
CN101687030B (zh) 2014-07-02
DK2121013T3 (en) 2015-01-19

Similar Documents

Publication Publication Date Title
BRPI0807828B8 (pt) composição compreendendo leveduras e usos das mesmas, bem como método para o crescimento de leveduras e kit para o cultivo de leveduras
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
BRPI0510716A (pt) uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
ECSP077888A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
ECSP10010095A (es) 2'-fluoro-2'-desoxitetrahidrouridinas como inhibidores de citidina desaminasa
ECSP099619A (es) Anticuerpos anti-robo4 y sus usos
BRPI0516323A (pt) construtos de rna
BRPI0916121A8 (pt) métodos para identificar câncer de próstata, composição, kit, método para identificar a presença de uma fusão gênica e uso de uma composição
MX339624B (es) Composiciones mejoradas de celulas y metodos para preparar las mismas.
PT2752484T (pt) Método para preparar um meio de cultura básico para células estaminais mesenquimais, meio de cultura básico para células estaminais mesenquimais, e agente terapêutico celular cultivado e diferenciado usando o mesmo
AR066395A1 (es) Reovirus que tienen secuencias modificadas
BRPI0611863A2 (pt) composto, bem como composiÇço e kit compreendendo o mesmo, composto intermediÁrio na preparaÇço do mesmo, mÉtodo para tratamento e uso do mesmo
CR9365A (es) Compuestos y metodos para la inhibicion de la protein-cinasa raf
MX2010004674A (es) Variantes de alfa-amilasa con propiedades alteradas.
BR112018015312A2 (pt) cepa fúngica isolada, cultura biologicamente pura, composição inoculante, kit, uso de uma cepa, e, método para aumentar quantidade/concentração de fosfato solúvel em um meio que contém fosfato insolúvel
WO2007008722A3 (en) Method for the isolation of rna from biological sources
AR058986A1 (es) Dominios de epsp sintetasa que confieren resistencia al glifosato
NO20070746L (no) Anvendelse av fosfaterte alkanoler som dispergente , emulgatorer, hydrotroper, fuktmidler og kompatabilitetsstoffer i blandinger for jordbruket.
CR9246A (es) Formulaciones terapeuticas del factor de crecimiento de queratinocitos
AR114504A1 (es) Regeneración de plantas genéticamente modificadas
BR112012029271A2 (pt) fungo isolado, método para produzir e kit para fabricar pelo menos um composto selecionado do grupo que consite de 1, 8-cineol, 1-metil-1,4-cicloexadieno, e (+) -a-metileno-a-fenchocanforona, molécula de ácido nucleico isolada de um fungo,e, método para gerar cepas mutantes de um fungo.
BRPI0513393A (pt) métodos para melhorar as caracterìsticas de crescimento de uma planta, e para produzir uma planta transgênica, planta ou célula de planta, construção, planta transgênica ou célula de planta, partes colhìveis e/ou produtos diretamente derivados das mesmas, uso de uma molécula de ácido nucleico snrk2 ou variante funcional da mesma ou uso de um polipeptìdeo snrk2 ou homólogo do mesmo, e, composição
BR112021026002A2 (pt) Regeneração e transformação melhorada de plantas com a ajuda de um gene de reforço grf1
AR059096A1 (es) Anticuerpos anti- efrina -b2 y metodos que usan estos
PE20210463A1 (es) Uso de composiciones que contienen streptomyces melanosporofaciens agl225 en el control de enfermedades de las plantas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/05/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/02/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF